ArticleBMC microbiology2025
Potential of a phage cocktail in the treatment of multidrug-resistant Klebsiella pneumoniae pulmonary infection in mice.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections.Cureus · 2026Review
- Gp8 mediates adsorption of bacteriophage vB_VpP_jzsmvpa to the host Vibrio parahaemolyticus.Antonie van Leeuwenhoek · 2026Article
- Prevalence, Virulence, and Pathogenic Mechanisms of Mastitis-AssociatedVeterinary sciences · 2026Review
- Phage therapy for multidrug-resistant pulmonary infections: bridging precision matching, lung delivery, host immunity, and clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Characterization of aFrontiers in cellular and infection microbiology · 2026Article
- Two novel lytic bacteriophages with antibiofilm activity against carbapenem-resistant Klebsiella pneumoniae infections.Infection · 2025Article
- Phage Therapy as a Novel Alternative to Antibiotics Through Adaptive Evolution and Fitness Trade-Offs.Antibiotics (Basel, Switzerland) · 2025Review
- Characterization and genomics of phage Henu2_3 against K1 Klebsiella pneumoniae and its efficacy in animal models.AMB Express · 2025Article
- Phage Therapy in Managing Multidrug-Resistant (MDR) Infections in Cancer Therapy: Innovations, Complications, and Future Directions.Pharmaceutics · 2025Review
- Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities.Bioengineering (Basel, Switzerland) · 2025Review
- Phage Therapy for Hospital-Acquired Respiratory Bacterial Infections: A Review.Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The emergence of multidrug-resistant Klebsiella pneumoniae, including carbapenem-resistant K. pneumoniae (CRKP), as one of the most common and notable superbugs, has long been a major threat to public health. As natural predators of bacteria, bacteriophages (or phages) can induce the lysis of bacterial cells. Herein, we report the isolation and characterization of two phages and their efficacy in the control of CRKP. Using the sequence type 11 (ST11) CRKP strain THR60 and its related strain THR60r as the host bacteria, phages GZ7 and GZ9 were isolated from hospital sewage, respectively. GZ7 is a myovirus with a head of 64 nm in diameter and a tail of 97 nm in length, and GZ9 is a siphovirus with a head of 67 nm in diameter and a tail of 175 nm in length. The host spectrum of a phage cocktail consisting of phages GZ7 and GZ9 was 82.4% (42/51 strains). An in vitro antibacterial activity assay demonstrated that the phage cocktail consisting of GZ7 and GZ9 effectively inhibited bacterial growth and suppressed the production of phage-resistant bacteria. In vivo experiment revealed that phage-treated mice exhibited lower K. pneumoniae burdens in the lungs compared to untreated control mice. Additionally, phage-treated mice experienced less body weight loss and had reduced levels of inflammatory cytokines in their lungs. Lung lesion conditions were significantly improved by phage therapy. Notably, the therapeutic effects of the GZ7 + GZ9 cocktail and GZ7 alone on mouse pulmonary infections were nearly equivalent. Therefore, phages GZ7 and GZ9 showed potential as alternatives to antibiotics for treating pneumonia caused by multidrug-resistant K. pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.